AUCTUS PUBLICATIONS ________________________________________ ADX Energy (ADX AU)C; target price of A$0.75 per share: Raising new equity to fund a high impact activity programme – ADX has raised A$13.5 mm of new equity priced at A$0.105 per share. One free-attaching option will be issued for evert two placement shares with an exercise price of A$0.15 per share and an expiry date of 08/05/2026. The proceeds from the raise will fund (1) the production testing of the 450 m gas column encountered at ...
Dorchester Minerals, L.P. Announces First Quarter Results DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today the Partnership’s net income for the quarter ended March 31, 2024 of $18,167,000, or $0.44 per common unit. A comparison of the Partnership’s consolidated results for the quarter ended March 31, 2024 and 2023 are set forth below: Three Months Ended March 31, 2024 2023Operating Revenues $30,979,000 $40,167,000Net Income $18,167,000 $28,070,000Net Income Per Common Unit $0.44 $0.71 The Partnership previously ...
Real Estate - Aroundtown shows successful result of GBP & USD Hybrid exchange and tender. Public Storage 1Q24: Slightly softer but no real concerns for credit investors. WP Carey 1Q24: Slight miss, but strong cash balance and liquidity
AMWELL ANNOUNCES RESULTS FOR FIRST QUARTER 2024 Boston, May 01, 2024 (GLOBE NEWSWIRE) -- (NYSE: AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the first quarter ended March 31, 2024. Visit Amwell’s investor relations website at to view the first quarter 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Wednesday, May 1. The call can be accessed via a live audio webcast at or by dialing 1-888-510-2008 for U.S. participants or...
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, announced today that the first patient in its Phase 2 clinical trial evaluating INB-400 in patients with newly diagnosed glioblastoma multiforme (GBM) has been successfully dosed at the Cleveland Clinic in Ohio. INB-400 is the Company’s first autologous gamma-delta T cell therapy product candidate genetically engineered to survive chem...
Amwell Releases 2024 Corporate Responsibility Report Report demonstrates company progress toward enabling digital healthcare with purpose Boston, April 29, 2024 (GLOBE NEWSWIRE) -- ® (NYSE: AMWL), a leader in hybrid care enablement, today announced the release of its 2024 Corporate Responsibility Report, which details the company’s latest progress across environmental, social, and governance (ESG) topics and highlights Amwell’s growing positive impact on key stakeholders and the communities it serves. “Corporate responsibility is fundamental to our mission to transform healthcare, wh...
AUCTUS PUBLICATIONS ________________________________________ ADX Energy (ADX AU)C; target price of A$1.00 per share: Important step to unlock Sicily – The Italian ministry has informed ADX that it will be granted the d 363C.R-.AX gas exploration permit in the Sicily Channel. In addition, the Regional Administrative Court of Rome has annulled the Plan for the Sustainable Energy Transition of Eligible Areas that prevented the oil redevelopment, appraisal and exploration activities on the licence. ...
Amwell to Participate in Upcoming Investor Conference Boston, April 25, 2024 (GLOBE NEWSWIRE) -- ® (NYSE: AMWL), a leader in hybrid care enablement, announced that the company will participate in the Needham Technology, Media and Consumer Conference. Robert Shepardson, Amwell chief financial officer, will participate in a fireside chat on Tuesday, May 14, at a time to be determined, along with one-on-one investor meetings throughout the day. An audio webcast of the fireside chat will be available at About Amwell Amwell is a leading hybrid care delivery enablement platform ...
NEW CANAAN, Conn.--(BUSINESS WIRE)-- Bankwell Financial Group, Inc. (NASDAQ: BWFG) reported GAAP net income of $3.8 million, or $0.48 per share for the first quarter of 2024, versus $10.4 million, or $1.33 per share, for the same period in 2023. Pre-tax, pre-provision net revenue ("PPNR") was $8.8 million, or $1.14 per share, for the first quarter of 2024, versus $14.4 million, or $1.89 per share for the same period in 2023. The Company's Board of Directors declared a $0.20 per share cash dividend, payable May 21, 2024 to shareholders of record on May 10, 2024. We recommend reading this ea...
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. Details of the oral presentation are as follows: Title: Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product; Immunophenotyping...
Comscore to Announce First Quarter 2024 Financial Results RESTON, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Comscore, Inc. (Nasdaq: SCOR), a trusted partner for planning, transacting and evaluating media, today announced that it plans to hold a conference call to discuss its financial results for the first quarter ended March 31, 2024 on Tuesday, May 7th at 5:00 p.m. ET. Interested parties may access the conference call via live webcast at , or participate via telephone by registering in advance at . Upon registration, all telephone participants will receive the dial-in number along ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.